Topics


Biosimilars


Are Biosimilars a safe and cost effective alternative for IBD patients?


Choosing a class of biologic for your patient


Choosing an IBD Therapy Beyond Conventional Therapy


Chromoendoscopy - Not endoscopic


De-escalation or discontinuation of therapy in IBD patients that have achieved remission


Drug pipeline


How to treat patients postoperatively


Inflammatory Bowel & Rheumatologic Disease


Microbiome


Nutrition based therapies: Are Nutrition based therapies essential or a distraction in the treatment of IBD?


Optimizing Biologic Therapies using Therapeutic Drug Monitoring


Optimal Treatment strategies for IBD


Perspectives on monotherapy vs combination therapy for IBD


Perioperative therapies: The safety and outcomes benefits or harm


Perspective of a Rheumatologist


Post-Operative Treatment in IBD


Potential New Pathways and Agents in the Management of IBD


Redefining Disease Severity in IBD


Role of Chromoendoscopy for Dysplasia Surveillance


Surgical Indication and Management of the IBD Patient


Therapeutic Drug Monitoring: Reactive versus Proactive


Top Down vs Step up therapy



Advanced Nurse Practitioners

Beyond Conventional Therapy in IBD


Diagnostic Testing for IBD and risk stratification.


Diet and IBD – What really matters about diet and nutrition for IBD patients


Health maintenance for IBD patients


How to obtain a biologic for a patient


Ostomies


Starting, monitoring and potential side effects of Mesalamine and immune modulators


The expanding role of a pharmacist in treating the IBD patient


Travel abroad for the patient with IBD


Upcoming Conferences


Speakers


Anita

Afzali



Leonard

Baidoo



William

DePaolo



Heidi

Drescher



Brian

Feagan



Mika

Sinanan



Media